Search details
1.
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Breast Cancer Res Treat
; 204(2): 289-297, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38155272
2.
Body composition and breast cancer risk and treatment: mechanisms and impact.
Breast Cancer Res Treat
; 186(2): 273-283, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33475878
3.
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Breast Cancer Res Treat
; 183(3): 729-739, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32720114
4.
Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer.
Breast Cancer Res Treat
; 179(2): 435-443, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31620935
5.
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
BMC Cancer
; 20(1): 430, 2020 May 18.
Article
in English
| MEDLINE | ID: mdl-32423453
6.
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer
; 120(12): 1105-1112, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31097774
7.
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
Breast Cancer Res Treat
; 171(2): 501-511, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-29915946
8.
[Breast-Conserving Surgery Using Real-Time Virtual Sonography in a Breast Cancer Patient Who Received Neoadjuvant Chemotherapy - ACase Report].
Gan To Kagaku Ryoho
; 43(12): 1461-1463, 2016 Nov.
Article
in Japanese
| MEDLINE | ID: mdl-28133023
9.
[The Case of a Patient with Invasive Lobular Carcinoma with Solitary Metastasis in Pectoralis Major Muscle].
Gan To Kagaku Ryoho
; 42(12): 1815-7, 2015 Nov.
Article
in Japanese
| MEDLINE | ID: mdl-26805182
10.
[Long-Term Outcome of Radiofrequency Ablation Therapy for Breast Cancer].
Gan To Kagaku Ryoho
; 42(12): 1788-90, 2015 Nov.
Article
in Japanese
| MEDLINE | ID: mdl-26805173
11.
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.
Clin Cancer Res
; 30(11): 2424-2432, 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38629963
12.
Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling.
Res Sq
; 2023 Oct 28.
Article
in English
| MEDLINE | ID: mdl-37961619
13.
Inflammatory breast cancer biomarker identification by simultaneous TGIRT-seq profiling of coding and non-coding RNAs in tumors and blood.
medRxiv
; 2023 May 30.
Article
in English
| MEDLINE | ID: mdl-37398275
14.
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
Biomedicines
; 11(3)2023 Feb 28.
Article
in English
| MEDLINE | ID: mdl-36979714
15.
Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Expert Opin Ther Targets
; 26(5): 405-425, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35574694
16.
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.
Sci Adv
; 8(50): eabn7983, 2022 12 16.
Article
in English
| MEDLINE | ID: mdl-36525493
17.
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer.
Cancers (Basel)
; 13(11)2021 May 28.
Article
in English
| MEDLINE | ID: mdl-34071219
18.
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 28.
Article
in English
| MEDLINE | ID: mdl-34638323
19.
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
PLoS One
; 16(4): e0250057, 2021.
Article
in English
| MEDLINE | ID: mdl-33861773
20.
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
Biomedicines
; 9(7)2021 Jun 28.
Article
in English
| MEDLINE | ID: mdl-34203351